pembrolizumab
merck
['melanoma', 'pembro']
#immunotherapy for desmoplastic melanoma. the overall response rate (orr) to pembrolizumab monotherapy was 89%, including a crr of 33%. at 2 years, progression-free survival (pfs) was 74% and overall survival was 89%.
#aacr23 
Pancreatic cancer researcher and GI pathologist. Striving to improve the lives of patients with cancer. May or may not be notable.